Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares some updates from the MajesTEC-1 trial (NCT04557098) investigating the use of teclistamab, a bispecific T-cell engager (BiTE), for the treatment of patients with relapsed/refractory (R/R) multiple myeloma. Dr Popat highlights the improved response rate and progression-free survival (PFS) observed in patients, and further discusses the improved quality of life reported in patient questionnaires. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.